Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 13, 2023 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer

NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
February 01, 2023 17:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
February 01, 2023 07:01 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
January 03, 2023 17:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
December 01, 2022 17:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- ZentalisTM Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
November 09, 2022 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates

Six sponsored studies with potentially first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from...
November 08, 2022 07:01 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
November 01, 2022 17:38 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
October 24, 2022 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

NEW YORK and SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
October 17, 2022 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

NEW YORK and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...